▟ Vinebot intrinsic value, daily

← back

WTW Willis Towers Watson

insurance · valued with opus medium conviction · deep-dived 2026-10-30

SELL
Intrinsic value$142.03
Price (at call)$320.73
Margin of safety -55.7%
vs market (rating basis) -39.1%

Quality broker priced near 320 is now over twice book-based value; fundamentals are unchanged, so discipline holds.

The story

WTW is an asset-light, fee-based broker and consulting franchise with sticky corporate clients, low credit risk and recurring revenue. Operating margin has recovered to 22.8% after the prior year's one-off hit, and trailing ROE of 19.6% sits in line with the normalized level I already used. Book equity is mostly goodwill and is kept small by steady buybacks, so a book-based residual income model will undervalue this business against a market that prices it on fee earnings.

I'm keeping the drivers unchanged. Trailing ROE of 19.6% confirms 19% as a sustainable through-the-cycle level, but I won't extrapolate a peak margin year. Book growth stays modest because buybacks absorb most retained earnings, and the terminal rate of 3.5% is below the 4.99% risk-free rate. Nothing in the new data justifies changing the beta or the failure probability for a low-leverage broker.

Value drivers

Return on equity (normalized)19.0%
Book-value growth (Y1)4.0%
Terminal book growth3.5%
Beta0.95
Failure probability0.7%
Cost of equity9.3%

Valuation bridge

PV of excess returns3.66B
PV of terminal excess1.65B
Equity value13.19B
÷ shares → per share$142.03

Projected excess returns on equity

YrBook equityROEExcess returnPV
17.98B 19.0%776.54M 710.70M
28.30B 18.1%736.30M 616.74M
38.62B 17.3%691.23M 529.90M
48.96B 16.4%641.12M 449.81M
59.30B 15.6%585.75M 376.12M
69.65B 14.7%524.91M 308.48M
710.01B 13.8%458.40M 246.55M
810.38B 13.0%385.99M 190.00M
910.75B 12.1%307.50M 138.53M
1011.14B 11.3%222.72M 91.83M

Key risks

  • A softening commercial P&C pricing cycle reduces commission growth and squeezes margins
  • Heavy buybacks and goodwill leave tangible book negative and add leverage, so the business has less cushion in a downturn
  • Organic growth slows in Health, Wealth & Career consulting, and there is execution risk in portfolio reshaping and M&A

Catalysts

  • Margin expansion holds above 22%, with mid-single-digit organic growth
  • Large buybacks continue and lift EPS even if book equity stays flat

History

DatePriceIntrinsicMoSRating
2026-10-30$320.73 $142.03 -55.7% SELL
2026-09-29$292.11 $139.70 -52.2% SELL
2026-08-27$343.12 $145.24 -57.7% SELL
2026-07-27$295.11 $139.02 -52.9% SELL
2026-06-23$257.55 $139.62 -45.8% SELL